Navigation Links
Cellectis bioresearch Establishes The Genome Customization Award (TGCA)
Date:6/16/2010

PARIS, June 16 /PRNewswire/ -- Cellectis bioresearch, the specialist in genome customization and a subsidiary of Cellectis (Alternext: ALCLS), announced today the first edition of The Genome Customization Award, for academic research teams across the world who are undertaking targeted modification of the genome of a cell line or that of a model organism using one or more meganucleases provided by Cellectis bioresearch.

"Through this award, Cellectis bioresearch aims at spreading the use of meganucleases for genome customization, throughout the Life Sciences community," explained Marc Le Bozec, CEO of Cellectis bioresearch. Priority will be given to innovative projects allowing a technological breakthrough.

The winning academic team will receive 15,000 euro (US$18,000) to partially fund one postdoctoral fellow recruited to work on the project, for one year, with a possible renewal for a second year.

The deadline for submitting applications is October 1, 2010. The winner will be announced on December 15, 2010, by a selection committee composed of respected genetic experts at some of the most well regarded academic institutions including:

  • Prof. Rodney J. Rothstein (Columbia University, New York, USA, Committee Chairman)
  • Prof. James E. Haber (Brandeis University, Waltham, USA)
  • Prof. Alain Fischer (Hopital Necker – Enfants Malades, Paris, France).

For full program detail or to apply, go to http://www.cellectis-bioresearch.com/award/.

About Cellectis bioresearch

Cellectis bioresearch was incorporated as a subsidiary of Cellectis (Alternext: ALCLS) in June 2008. It provides life science researchers with easy-to-use tools for genome customization. These tools, based on meganucleases, enable the engineering of cells with optimized features for drug discovery, protein production and gene functional study.

More information at www.cellectis-bioresearch.com

About Cellectis

Cellectis is a pioneer in the field of genome engineering. The company designs and markets innovative tools -meganucleases. These molecular scissors enable targeted modifications to DNA, with applications in the research, biomanufacturing, agrobiotechnology and therapeutic sectors.

To date, Cellectis has formed over 20 academic research partnerships and has established more than 50 agreements with pharmaceutical laboratories, seed producers and biotech companies across the world. The company holds exclusive rights to a portfolio of over 260 patents granted or pending.

Since 2007, Cellectis has been listed on the NYSE-Euronext Alternext market (code : ALCLS) in Paris and has secured over 70 million euro in funding since inception.

More information at www.cellectis.com

Follow us on Twitter at www.twitter.com/cellectis

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives. Such forward-looking statements are based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company's products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavorable developments in connection with these and other risks and uncertainties described, in particular, in the Company's prospectus prepared in connection with its IPO and on which the French Autorite des marches financiers ("AMF") granted its visa n° 07-023 on January 22, 2007, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.


'/>"/>
SOURCE Cellectis bioresearch
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Cellectis Sues Precision BioSciences for Infringement of its Patents Concerning Meganuclease Technology
2. Cellectis and Regeneron Sign an Agreement Over the use of Homologous Recombination Technology
3. Monsanto Licenses Use of Cellectis Innovative Genome Modification Technology
4. Cellectis to Present at the American Society of Gene & Cell Therapy Annual Meeting
5. Cellectis to Present at the FASEB Summer Research Conference on Genome Engineering
6. Cardinal Health Establishes $1 Million Grant Fund for Initiatives That Improve Quality, Safety of Patient Care
7. N.C. Takes Biofuels Leadership, Establishes New Endeavor With $5 Million State Appropriation
8. Cellumen Establishes Collaboration in Breast Cancer Patient Stratification
9. Ardea Biosciences Establishes Scientific Advisory Board for HIV Program
10. Rosetta Genomics Establishes Medical Advisory Board
11. Ardea Biosciences Establishes Scientific Advisory Board for Inflammation Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... ... ... Studies indicate that replacing damaged brain cells with those derived from human embryonic ... not been determined is the optimal stage during differentiation of the stem cells that ... coming out of Singapore, recently published in STEM CELLS Translational Medicine journal may provide ...
(Date:6/27/2017)... , ... June 27, 2017 , ... ... Program (ESTCP), powder activated carbon (PAC)-based materials do not have negative short- or ... at a site contaminated with polychlorinated biphenyls (PCBs) located at the Puget Sound ...
(Date:6/26/2017)... ... June 26, 2017 , ... Third Wave Bioactives, LLC announces the addition of ... leading new business development and ensuring quality customer experience. , Brett brings ... industry in technical, marketing and sales roles. “Brett’s background working with customers and eye ...
(Date:6/23/2017)... ... 2017 , ... RURO, Inc., a leading LIMS, RFID, LIS ... growing Laboratory Information System. , LimitLIS® version 3 is includes new features that ... customization options. Each of these has been “under the microscope” in recent months ...
Breaking Biology Technology:
(Date:4/5/2017)... 2017  The Allen Institute for Cell Science today ... one-of-a-kind portal and dynamic digital window into the human ... first application of deep learning to create predictive models ... and a growing suite of powerful tools. The Allen ... future publicly available resources created and shared by the ...
(Date:3/30/2017)... March 30, 2017  On April 6-7, 2017, Sequencing.com ... Genome hackathon at Microsoft,s headquarters in ... will focus on developing health and wellness apps that ... Hack the Genome is the first hackathon for ... world,s largest companies in the genomics, tech and health ...
(Date:3/27/2017)... ROCKVILLE CENTRE, N.Y. , March 27, 2017 ... by Healthcare Information and Management Systems Society (HIMSS) ... Analytics Outpatient EMR Adoption Model sm . In ... top 12% of U.S. hospitals using an electronic ... recognized CHS for its high level of EMR ...
Breaking Biology News(10 mins):